Beijing Immunochina Pharmaceutical Raised ¥100M Yuan

On October 16, Beijing Immunochina Pharmaceutical Co., Ltd. announced the completion of a 100 million yuan C + round of financing, invested by Zhongguancun Longmen Fund. This round of financing will be mainly used to support the research and development of Yimiao Shenzhou's new tumor product pipeline and to accelerate the product launch process.

Established in 2015, Beijing Immunochina Pharmaceutical Co., Ltd. is devoted to developing innovative gene and cell therapies for curing malignant tumors. Immunochina has independently developed a new generation of CAR-T technology, which is leading in the field to achieve full-process serum-free production, large-scale gene vector preparation, high production success rate and long-term in vivo persistence of CAR-T cells. As a result, the efficacy and safety of  CAR-T products are greatly improved. Additionally, Immunochina owns spacious open and clean laboratories, as well as manufacturing facilities that fully meet regulations of China, US and EU, which guarantees one-stop CAR-T production at high quality.

Immunochina has been awarded various qualifications and honors, including the National High and New Tech Enterprises, Zhongguancun High and New Tech Enterprises, Zhongguancun Golden Seed Company, Beijing Science and Technology Project , Beijing "Nova Technology" Program, Beijing Scientific and Technology Enterprise Innovative Fund, Beijing "Young Eagle Talent", Beijing "Golden Bridge Seed Fund", Zhongguancun Frontier Reserve Project, Capital Health Development Scientific Research Project Fund, Beijing Natural Science Foundation General Project , China's Top 50 Most Valuable Investment Enterprises, Tsinghua University x-lab Annual Star and etc.

Zhongguancun Longmen Fund is a Chinese private equity base in Beijing.